

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rosana Kapeller-Libermann, David White, and Kyle J. MacBeth  
Continuation N/A Group No.: N/A  
Application No.:  
Filed: January 29, 2004 Examiner: N/A  
For: 2786, A NOVEL HUMAN AMINOPEPTIDASE

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement submitted herewith is being filed:  
☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits; whichever event occurred last but *before* the mailing date of either:

## CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Address"  
Mailing Label No. EV400464557US

## TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: January 29, 2004

  
Signature

Sean Hunziker

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI99-193CN2M**

- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**FEE PAYMENT**

2. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

Fee due \$0.00


**METHOD OF PAYMENT OF FEE**

3. ☐ Attached is a check in the amount of \$ \_\_\_\_\_.
- ☐ Charge Account No. 501668 in the amount of \$0.00.
- ☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

January 29, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By   
Mario Cloutier  
Limited Recognition Under 37 C.F.R. §10.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Rosana Kapeller-Libermann, David White, and Kyle J. MacBeth  
Continuation N/A Group No.: N/A  
Application No.:  
Filed: January 29, 2004 Examiner: N/A  
For: 2786, A NOVEL HUMAN AMINOPEPTIDASE

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements;
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449);
3. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted (AA, CA-CS)

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

- ☐ with sufficient postage as first class mail.

**37 C.F.R. SECTION 1.10\***

- ☒ as "Express Mail Post Office to Address"  
Mailing Label No. EV400464557US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: January 29, 2004

Signature



Sean Hunziker

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


**Identification of Prior Application in Which Listed Information Was Already Cited  
and for Which No Copies Are Submitted or Need Be Submitted**

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No. 10/056,253, filed on January 24, 2002.

The cited references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, the undersigned will provide additional copies upon request.

January 29, 2004

Respectfully submitted,  
MILLENNIUM PHARMACEUTICALS, INC.

By:   
Mario Cloutier  
Limited Recognition Under 37 C.F.R. §10.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitut for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>C mplete if Known</b>	
				Application Number	Not yet Assigned
				Filing Date	January 29, 2004
				First Named Inventor	Rosana Kapeller-Libermann, et al.
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	MP199-193CN2M

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Wh re Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	US 4,185,156		Umezawa et al.	01/22/1980	Column 1, Line 1 Column 2, Line 31

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD- YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>S attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japan's patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		Application Number	Not yet Assigned
		Filing Date	January 29, 2004
		First Named Inventor	Rosana Kapeller-Libermann, et al.
		Group Art Unit	N/A
		Examiner Name	N/A
Sheet	1	of	2
		Attorney Docket Number	MPI99-193CN2M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T 2
	CA	BLAST searches in DBEST, NRN, NRP and PATENT Databases	
	CB	Annotation on GenBank Accession No. U49278	
	CC	Anderson, "Human Gene Therapy," <i>Nature</i> , April 30, 1998, Vol. 392 Supp., pp. 25-30	
	CD	Beattie et al., Abstract, "The Use of Multiple Pin Peptide Synthesis in an Analysis of the Continuous Epitopes Recognized by Various Anti-(recombinant bovine growth hormone) Sera," <i>European Journal of Biochemistry</i> , November 15, 1992, pp. 59-66, Vol. 210, No. 1	
	CE	Bloecker et al., Nucleotide and Protein Databases, Direct Submission, EBI UK Accession No. Q9NP17	
	CF	Cadel et al., "Aminopeptidase B from the Rat Testis is a Bifunctional Enzyme Structurally Related to Leukotriene-A <sub>4</sub> Hydrolase," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, pp 2963-2968, Vol. 94	
	CG	Dedinsky et al., "Antigenic Determinants of Cytochrome P450 Superfamily and Their Classification," 8 <sup>th</sup> Russia Cytochrome P450 Int. Conf., 1994, Abstract No. 119832	
	CH	Draoui, et al., "Expression and Retinoid Modulation N-arginine Dibasic Convertase and an Aminopeptidase-B in Human Neuroblastoma Cell Lines," <i>Journal of Neuro-Oncology</i> , 1997, pp. 99-106, Vol. 31, No. 12	
	CI	Foulon, et al., "Aminopeptidase B (EC 3.4.11.6)," <i>International Journal of Biochemistry &amp; Cell Biology</i> , July 1999, pp. 747-750, Vol. 31, No. 7	
	CJ	Fukasawa, et al., "Molecular Cloning and Expression of Rat Liver Aminopeptidase B," <i>Journal of Biological Chemistry</i> , November 29, 1996, pp. 30731-30735, Vol. 271, No. 48	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin-top: 10px;">(use as many sheets as necessary)</p>				<h3 style="text-align: center; margin: 0;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">Not yet Assigned</td> </tr> <tr> <td>Filing Date</td> <td>January 29, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Rosana Kapeller-Libermann, et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>N/A</td> </tr> <tr> <td>Examiner Name</td> <td>N/A</td> </tr> <tr> <td>Attorney Docket Number</td> <td>MPI99-193CN2M</td> </tr> </table>		Application Number	Not yet Assigned	Filing Date	January 29, 2004	First Named Inventor	Rosana Kapeller-Libermann, et al.	Group Art Unit	N/A	Examiner Name	N/A	Attorney Docket Number	MPI99-193CN2M
Application Number	Not yet Assigned																
Filing Date	January 29, 2004																
First Named Inventor	Rosana Kapeller-Libermann, et al.																
Group Art Unit	N/A																
Examiner Name	N/A																
Attorney Docket Number	MPI99-193CN2M																
Sheet	2	of	2														

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		T 2
	CK	Kristensen, "Human Aminopeptidase B cDNA Cloning," Nucleotide and Protein Sequences, Direct Submission Oct. 2000, EBI UK Accession No. Q9H4A4		
	CL	NCI-CGAP, Nucleotide and Protein Sequences, Direct Submission, EBI UK Accession No. A1582355		
	CM	NCI-CGAP, Nucleotide and Protein Sequences, Direct Submission, EBI UK Accession No. AW167220		
	CN	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , 1994, pp. 491-495		
	CO	Piesse et al., "Human Aminopeptidase B on Chromosome 1q32.2:cDNA, Genomic Structure and Expression," Direct Submission May 1999, EBI UK Accession No. Q9H1D4		
	CP	Rudinger, "Characteristics of the Amino Acids and Components of a Peptide Hormone Sequence," <i>Peptide Hormones</i> , June 1976, pp 5-7/		
	CQ	Sancho, et al., "Role of UEV-1, an Inactive Variant of the E2 Ubiquitin-Conjugating Enzymes, in In Vitro Differentiation and Cell Cycle Behavior of HT-29-M6 Intestinal Mucosecretory Cells," <i>Molecular and Cellular Biology</i> , Jan. 1998, pp. 576-589, Vol. 18, No. 1		
	CR	Sugano, et al., Nucleotide and Protein Sequences, Direct Submission, EBI UK Accession No. AK026644		
	CS	VERMA, et al., "Gene Therapy – Promises, Problems and Prospects," <i>Nature</i> , September 18, 1997, Vol. 389, pp. 239-242		
Examiner Signature		Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.